BMY Down on Heart Drug Camzyos Failure in Late-Stage Study

  • Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.